{"id":43851,"date":"2015-09-17T11:25:58","date_gmt":"2015-09-17T16:25:58","guid":{"rendered":"https:\/\/content.findlaw-admin.com\/ability-legal\/contracts\/uncategorized\/pricing-agreement-monsanto-co.html"},"modified":"2015-09-17T11:25:58","modified_gmt":"2015-09-17T16:25:58","slug":"pricing-agreement-monsanto-co","status":"publish","type":"corporate_contracts","link":"https:\/\/corporate.findlaw.com\/contracts\/securities\/pricing-agreement-monsanto-co.html","title":{"rendered":"Pricing Agreement – Monsanto Co."},"content":{"rendered":"

PRICING AGREEMENT<\/strong><\/p>\n

\n

April 12, 2011<\/p>\n

\n

Goldman, Sachs & Co.
\n200 West Street
\nNew York, NY 10282<\/p>\n<\/p>\n

Merrill Lynch, Pierce, Fenner & Smith
\nIncorporated
\nOne Bryant Park
\nNew York, NY 10036<\/p>\n<\/p>\n

As Representatives of the several
\nUnderwriters named in Schedule I hereto.<\/p>\n<\/p>\n

Ladies and Gentlemen:<\/p>\n<\/p>\n

Monsanto Company, a Delaware corporation (the “Company”), proposes, subject
\nto the terms and conditions stated herein and in the Underwriting Agreement,
\ndated April 12, 2011 (the “Underwriting Agreement”), to issue and sell to the
\nUnderwriters named in Schedule I hereto (the “Underwriters”) the Securities
\nspecified in Schedule II hereto (the “Designated Securities”). Each of the
\nprovisions of the Underwriting Agreement is incorporated herein by reference in
\nits entirety, and shall be deemed to be a part of this Agreement to the same
\nextent as if such provisions had been set forth in full herein. Each of the
\nrepresentations and warranties set forth therein shall be deemed to have been
\nmade at and as of the date of this Pricing Agreement, except that each
\nrepresentation and warranty in Section 2 of the Underwriting Agreement which
\nrefers to the Prospectus and the Time of Sale Information shall be deemed to be
\na representation or warranty as of the date of the Underwriting Agreement in
\nrelation to the Prospectus and the Time of Sale Information (each as therein
\ndefined), and also a representation and warranty of the date of this Pricing
\nAgreement in relation to the Prospectus and the Time of Sale Information
\nrelating to the Designated Securities which are the subject of this Pricing
\nAgreement. Each reference to the Representatives herein and in the provisions of
\nthe Underwriting Agreement so incorporated by reference shall be deemed to refer
\nto you. Unless otherwise defined herein, terms defined in the Underwriting
\nAgreement are used herein as therein defined. The Representatives designated to
\nact on behalf of the Representatives and on behalf of each of the Underwriters
\nof the Designated Securities pursuant to Section 13 of the Underwriting
\nAgreement and the address of the Representatives referred to in such Section 13
\nare set forth at the end of Schedule II hereto.<\/p>\n<\/p>\n

\n

An amendment to the Registration Statement, or a supplement to the
\nProspectus, as the case may be, relating to the Designated Securities, in the
\nform heretofore delivered to you is now proposed to be filed with the
\nCommission.<\/p>\n

Subject to the terms and conditions set forth herein and in the Underwriting
\nAgreement incorporated herein by reference, the Company agrees to issue and sell
\nto each of the Underwriters, and each of the Underwriters agrees, severally and
\nnot jointly, to purchase from the Company, at the time and place and at the
\npurchase price to the Underwriters set forth in Schedule II thereto, the
\nprincipal amount of Designated Securities set forth opposite the name of such
\nUnderwriter in Schedule I hereto.<\/p>\n

Schedule III hereto sets forth the Free Writing Prospectuses, if any,
\nincluded in the Time of Sale Information.<\/p>\n

Schedule IV hereto sets forth the Pricing Term Sheet relating to the
\nDesignated Securities to be filed pursuant to Rule 433 under the Securities Act.\n<\/p>\n

If the foregoing is in accordance with your understanding, please sign and
\nreturn to us two counterparts hereof, and upon acceptance hereof by you, on
\nbehalf of each of the Underwriters, this letter and such acceptance hereof,
\nincluding the provisions of the Underwriting Agreement incorporated herein by
\nreference, shall constitute a binding agreement between each of the Underwriters
\nand the Company. It is understood that your acceptance of this letter on behalf
\nof each of the Underwriters is or will be pursuant to the authority set forth in
\na form of Agreement among Underwriters, the form of which shall be submitted to
\nthe Company for examination, upon request, but without warranty on the part of
\nthe Representatives as to the authority of the signers thereof.<\/p>\n

2<\/p>\n

\n

\n\n\n\n\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n\n

Very truly yours,<\/p>\n

Monsanto Company<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
<\/td>\n\n

By:<\/p>\n<\/td>\n

\n

\/s\/ Tom D. Hartley<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n\n

Name:<\/p>\n<\/td>\n

\n

Tom D. Hartley<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n\n

Title:<\/p>\n<\/td>\n

\n

Vice President and Treasurer<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n\n

Accepted as of the date hereof:<\/p>\n

Goldman, Sachs & Co.
\nMerrill Lynch, Pierce, Fenner & Smith
\nIncorporated<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
<\/td>\n\n

By:<\/p>\n<\/td>\n

\n

Goldman, Sachs & Co.<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n\n

By:<\/p>\n<\/td>\n

\n

\/s\/ Goldman, Sachs & Co.<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n\n

Name:<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n\n

Title:<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/tr>\n
<\/td>\n\n

Merrill Lynch, Pierce, Fenner & Smith
\nIncorporated<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
<\/td>\n\n

By:<\/p>\n<\/td>\n

\n

\/s\/ Jim Probert<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n\n

Name:<\/p>\n<\/td>\n

\n

Jim Probert<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n\n

Title:<\/p>\n<\/td>\n

\n

Managing Director<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

On behalf of each of themselves and
\neach of the other Underwriters<\/p>\n

\n

SCHEDULE I<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n\n

Principal Amount of<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Underwriter<\/p>\n<\/td>\n

<\/td>\n\n

Notes due 2016<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Goldman, Sach & Co.<\/p>\n<\/td>\n

<\/td>\n\n

$<\/p>\n<\/td>\n

\n

81,000,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Merrill Lynch, Pierce, Fenner & Smith<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Incorporated<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

81,000,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Barclays Capital Inc.<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

37,500,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Mitsubishi UFJ Securities (USA), Inc.<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

37,500,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Citigroup Global Markets Inc.<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

8,148,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

J.P. Morgan Securities LLC<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

8,148,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

RBS Securities Inc.<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

6,471,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Morgan Stanley & Co. Incorporated<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

6,471,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Credit Agricole Securities (USA) Inc.<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

3,957,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Mizuho Securities USA Inc.<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

3,957,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Rabo Securities USA, Inc.<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

3,957,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Wells Fargo Securities, LLC<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

3,957,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

BNY Mellon Capital Markets, LLC<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

2,562,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Fifth Third Securities, Inc.<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

2,562,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Santander Investment Securities Inc.<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

2,562,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

SG Americas Securities, LLC<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

2,562,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Standard Chartered Bank<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

2,562,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

The Williams Capital Group, L.P.<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

2,562,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

UniCredit Capital Markets LLC<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

2,562,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Total<\/p>\n<\/td>\n

<\/td>\n\n

$<\/p>\n<\/td>\n

\n

300,000,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n

SCHEDULE II<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Title of Designated Securities:<\/strong><\/p>\n<\/td>\n

<\/td>\n\n

2-3\/4% Notes due 2016<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Aggregate Principal Amount:<\/strong><\/p>\n<\/td>\n

<\/td>\n\n

$300,000,000<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Price to Public:<\/strong><\/p>\n<\/td>\n

<\/td>\n\n

99.787% of the principal amount of the Designated Securities, plus accrued
\ninterest from April 15, 2011.<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Purchase Price by Underwriters:<\/strong><\/p>\n<\/td>\n

<\/td>\n\n

99.187% of the principal amount of the Designated Securities, plus accrued
\ninterest from April 15, 2011.<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Form of Designated Securities:<\/strong><\/p>\n<\/td>\n

<\/td>\n\n

Book-entry only form represented by one or more global securities deposited
\nwith The Depository Trust Company or its designated custodian, to be made
\navailable for checking by the Representatives at least twenty-four hours prior
\nto the Time of Delivery.<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Maturity:<\/strong><\/p>\n<\/td>\n

<\/td>\n\n

April 15, 2016<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Interest Rate:<\/strong><\/p>\n<\/td>\n

<\/td>\n\n

2.750%<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Interest Payment Dates<\/strong><\/p>\n<\/td>\n

<\/td>\n\n

April 15 and October 15, commencing October 15, 2011<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Record Dates<\/strong><\/p>\n<\/td>\n

<\/td>\n\n

April 1 and October 1, immediately preceding the Interest Payment Dates<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Redemption Provisions:<\/strong><\/p>\n<\/td>\n

<\/td>\n\n

Make-Whole T+10 basis points<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Time of Delivery:<\/strong><\/p>\n<\/td>\n

<\/td>\n\n

April 15, 2011<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Closing Location:<\/strong><\/p>\n<\/td>\n

<\/td>\n\n

Mayer Brown LLP, 71 S. Wacker, Chicago, IL 60606<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Names and Addresses of Designated Representatives<\/strong><\/p>\n<\/td>\n

<\/td>\n\n

Goldman, Sachs & Co
\n200 West Street
\nNew York, New York 10282<\/p>\n

Merrill Lynch, Pierce, Fenner & Smith Incorporated
\nOne Bryant Park
\nNew York, NY 10036<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Address for Notices, etc.<\/strong><\/p>\n<\/td>\n

<\/td>\n\n

Goldman, Sachs & Co
\n200 West Street
\nNew York, New York 10282
\nAttention: Registration Department<\/p>\n

Merrill Lynch, Pierce, Fenner & Smith Incorporated
\nOne Bryant Park
\nNew York, NY 10036
\nAttention: High Grade Debt Capital Markets Transaction Management
\nFacsimile: (212) 901-7881<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n

SCHEDULE III<\/strong><\/p>\n

Free Writing Prospectuses included in the Time of Sale
\nInformation<\/strong><\/p>\n

\n

SCHEDULE IV<\/strong><\/p>\n

Form for Pricing Term Sheet<\/strong><\/p>\n

$300,000,000
\nMonsanto Company<\/p>\n

2-3\/4% Senior Notes due 2016<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Issuer:<\/p>\n<\/td>\n

<\/td>\n\n

Monsanto Company<\/p>\n<\/td>\n<\/tr>\n

\n

Ratings (Moody153s\/S&P\/Fitch)*:<\/p>\n<\/td>\n

<\/td>\n\n

A2\/A+\/A+<\/p>\n<\/td>\n<\/tr>\n

\n

Format<\/p>\n<\/td>\n

<\/td>\n\n

SEC Registered<\/p>\n<\/td>\n<\/tr>\n

\n

Ranking<\/p>\n<\/td>\n

<\/td>\n\n

Senior Unsecured<\/p>\n<\/td>\n<\/tr>\n

\n

Size:<\/p>\n<\/td>\n

<\/td>\n\n

$300,000,000<\/p>\n<\/td>\n<\/tr>\n

\n

Trade Date:<\/p>\n<\/td>\n

<\/td>\n\n

April 12, 2011<\/p>\n<\/td>\n<\/tr>\n

\n

Settlement Date:<\/p>\n<\/td>\n

<\/td>\n\n

T+3; April 15, 2011<\/p>\n<\/td>\n<\/tr>\n

\n

Maturity:<\/p>\n<\/td>\n

<\/td>\n\n

April 15, 2016<\/p>\n<\/td>\n<\/tr>\n

\n

Interest Payment Dates:<\/p>\n<\/td>\n

<\/td>\n\n

April 15 and October 15, commencing October 15, 2011<\/p>\n<\/td>\n<\/tr>\n

\n

Benchmark Treasury:<\/p>\n<\/td>\n

<\/td>\n\n

UST 2.25% due March 31, 2016<\/p>\n<\/td>\n<\/tr>\n

\n

Benchmark Treasury Price and Yield:<\/p>\n<\/td>\n

<\/td>\n\n

100-08; 2.196%<\/p>\n<\/td>\n<\/tr>\n

\n

Spread to Benchmark Treasury:<\/p>\n<\/td>\n

<\/td>\n\n

60 basis points<\/p>\n<\/td>\n<\/tr>\n

\n

Yield to Maturity:<\/p>\n<\/td>\n

<\/td>\n\n

2.796%<\/p>\n<\/td>\n<\/tr>\n

\n

Coupon:<\/p>\n<\/td>\n

<\/td>\n\n

2.750%<\/p>\n<\/td>\n<\/tr>\n

\n

Day Count:<\/p>\n<\/td>\n

<\/td>\n\n

30\/36<\/p>\n<\/td>\n<\/tr>\n

\n

Public Offering Price:<\/p>\n<\/td>\n

<\/td>\n\n

99.787%<\/p>\n<\/td>\n<\/tr>\n

\n

Redemption Provisions:<\/p>\n<\/td>\n

<\/td>\n\n

Make-Whole T+10 basis points<\/p>\n<\/td>\n<\/tr>\n

\n

Bookrunners:<\/p>\n<\/td>\n

<\/td>\n\n

Goldman, Sachs & Co.<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

Merrill Lynch, Pierce, Fenner & Smith
\nIncorporated<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

Barclays Capital Inc.<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

Mitsubishi UFJ Securities (USA), Inc.<\/p>\n<\/td>\n<\/tr>\n

\n

Co-Managers:<\/p>\n<\/td>\n

<\/td>\n\n

Citigroup Global Markets Inc.<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

J.P. Morgan Securities LLC<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

Morgan Stanley & Co. Incorporated<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

RBS Securities Inc.<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

Credit Agricole Securities (USA) Inc.<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

Mizuho Securities USA Inc.<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

Rabo Securities USA, Inc.<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

Wells Fargo Securities, LLC<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

BNY Mellon Capital Markets, LLC<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

Fifth Third Securities, Inc.<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

Santander Investment Securities Inc.<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

SG Americas Securities, LLC<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

Standard Chartered Bank<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n\n\n\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n\n

The Williams Capital Group, L.P.<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

UniCredit Capital Markets LLC<\/p>\n<\/td>\n<\/tr>\n

\n

CUSIP\/ISIN:<\/p>\n<\/td>\n

<\/td>\n\n

611662 BM8 \/ US611662BM89<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

*<\/p>\n<\/td>\n

<\/td>\n\n

An explanation of the significance of ratings may be obtained from the rating
\nagencies. Generally, rating agencies base their ratings on such material and
\ninformation, and such of their own investigations, studies and assumptions, as
\nthey deem appropriate. The rating of the notes should be evaluated independently
\nfrom similar ratings of other securities. A credit rating of a security is not a
\nrecommendation to buy, sell or hold securities and may be subject to review,
\nrevision, suspension, reduction or withdrawal at any time by the assigning
\nrating agency.<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The issuer has filed a registration statement (including a
\nprospectus) with the SEC for the offering to which this communication relates.
\nBefore you invest, you should read the prospectus in that registration statement
\nand other documents the issuer has filed with the SEC for more complete
\ninformation about the issuer and this offering. You may get these documents for
\nfree by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the
\nissuer, any underwriter or any dealer participating in the offering will arrange
\nto send you the prospectus if you request it by calling Goldman, Sachs & Co.
\ntoll-free at (866) 471-2526 or by email to prospectus-ny@ny.email.gs.com<\/u>
\nor by calling Merrill Lynch, Pierce, Fenner & Smith Incorporated toll-free
\nat (800) 294-1322.<\/strong><\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"_stopmodifiedupdate":true,"_modified_date":"","_cloudinary_featured_overwrite":false},"corporate_contracts_companies":[8249],"corporate_contracts_industries":[9451],"corporate_contracts_types":[9629,9634],"class_list":["post-43851","corporate_contracts","type-corporate_contracts","status-publish","hentry","corporate_contracts_companies-monsanto-co","corporate_contracts_industries-manufacturing__chemicals","corporate_contracts_types-securities","corporate_contracts_types-securities__underwriting"],"acf":[],"_links":{"self":[{"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/corporate_contracts\/43851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/corporate_contracts"}],"about":[{"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/types\/corporate_contracts"}],"wp:attachment":[{"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/media?parent=43851"}],"wp:term":[{"taxonomy":"corporate_contracts_companies","embeddable":true,"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/corporate_contracts_companies?post=43851"},{"taxonomy":"corporate_contracts_industries","embeddable":true,"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/corporate_contracts_industries?post=43851"},{"taxonomy":"corporate_contracts_types","embeddable":true,"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/corporate_contracts_types?post=43851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}